Tamsulosin

Generic Name: Tamsulosin

Brand Names: Flomax, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅S

CAS Number: 106133-20-4

Unique Ingredient Identifier: G3P28OML5I

Background: Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication: Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Associated Therapies: -

Clinical Trials

Medical Expulsive Therapy of Single Distal Ureteral Stones

Not Applicable

Completed

Conditions: Ureteral Calculi

Interventions: Drug: Placebo
Drug: Tamsulosin

First Posted Date: 2009-01-29

Last Posted Date: 2010-05-25

Lead Sponsor: University of Zurich

Target Recruit Count: 100

Registration Number: NCT00831701

Locations: 🇨🇭
Department of Urology, University Hospital Zürich, Switzerland, Zurich, Switzerland

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

Phase 2

Completed

Conditions: Bladder, Neurogenic

Interventions: Drug: Placebo
Drug: tamsulosin hydrochloride

First Posted Date: 2008-11-24

Last Posted Date: 2015-10-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 231

Registration Number: NCT00796614

Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia
Benign Prostatic Hypertrophy
Overactive Bladder

Interventions: Drug: Tamsulosin hydrochloride
Drug: Solifenacin succinate

First Posted Date: 2008-10-13

Last Posted Date: 2013-02-15

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 638

Registration Number: NCT00771394

Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia

Phase 4

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Tamsulosin

First Posted Date: 2008-06-19

Last Posted Date: 2018-11-02

Lead Sponsor: Siami, Paul F., M.D.

Target Recruit Count: 63

Registration Number: NCT00701779

Locations: 🇺🇸
Research Institute of Deaconess Clinic, Evansville, Indiana, United States

Prevention of Acute Voiding Difficulty After Radical Proctectomy

Phase 3

Completed

Conditions: Rectal Cancer
Urinary Retention

Interventions: Drug: Tamsulosin

First Posted Date: 2008-02-05

Last Posted Date: 2011-07-20

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 100

Registration Number: NCT00606983

Locations: 🇰🇷
Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients

Not Applicable

Completed

Conditions: Nephrolithiasis
Ureteral Calculi

Interventions: Drug: tamsulosin
Drug: Standard therapy with ibuprofen and oxycodone.

First Posted Date: 2008-01-25

Last Posted Date: 2008-01-25

Lead Sponsor: MaineHealth

Target Recruit Count: 81

Registration Number: NCT00600405

Locations: 🇺🇸
Maine Medical Center, Portland, Maine, United States

Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Placebo
Drug: Tadalafil
Drug: Tamsulosin

First Posted Date: 2007-10-05

Last Posted Date: 2010-11-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 151

Registration Number: NCT00540124

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of